Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...

A recent study published in JAMA Psychiatry has uncovered promising evidence suggesting that glucagon-like peptide-1 (GLP-1) ...

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced ...

(HealthDay News) — The US Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), a glucagon-like peptide-1 (GLP-1) receptor agonist ...

These medications were sitagliptin, liraglutide, glimepiride, or insulin glargine U-100. Sitagliptin, liraglutide, and ...

Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...

A recent breakthrough in medical research offers exciting possibilities for people dealing with diabetes and obesity. This ...

Diabetes Care. 2015;38(6):1058-1066. The safety profile of liraglutide is under continuous surveillance through meticulous routine pharmacovigilance, with any cases of pancreatitis being analyzed ...

GLP-1 receptor agonists (GLP-1RAs), including liraglutide, semaglutide, and tirzepatide, were originally developed for managing type-2 diabetes. However, due to their success in helping with ...

Only 34 of 79 websites stated that compounded drugs were not FDA approved; 39 websites did not report adverse effects, warnings.

Liraglutide, sold under the brand name Victoza for diabetes, is an earlier iteration in the same class as semaglutide, the active ingredient in Ozempic. Both are sold by Danish drug giant Novo ...